ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesC79.9

C79.9

Billable

Secondary malignant neoplasm of unspecified site

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 C79.9 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of unspecified site.

Key Diagnostic Point:

C79.9 refers to secondary malignant neoplasms, which are cancers that have metastasized from a primary site to other locations in the body. This code is used when the specific site of the metastasis is not documented or is unknown. Metastatic disease can arise from various primary cancers, including but not limited to breast, lung, prostate, and colorectal cancers. The staging of metastatic disease is crucial for treatment planning and prognosis, typically classified using the TNM system (Tumor, Node, Metastasis). Patients with secondary malignant neoplasms often require palliative care, focusing on symptom management and quality of life, especially when the disease is advanced and curative treatment is not feasible. Accurate coding of C79.9 is essential for appropriate reimbursement and to reflect the complexity of the patient's condition, particularly in cases where the primary site is unknown, necessitating thorough documentation of clinical findings and diagnostic efforts.

Code Complexity Analysis

Complexity Rating: High

High Complexity

Complexity Factors

  • Determining the primary site of cancer can be challenging.
  • Documentation may lack specificity regarding the metastatic site.
  • Requires knowledge of staging systems and palliative care considerations.
  • Potential for misclassification if primary site is later identified.

Audit Risk Factors

  • Insufficient documentation of the primary cancer site.
  • Lack of clarity in the clinical narrative regarding metastasis.
  • Inconsistent staging information.
  • Failure to update coding when the primary site is identified.

Specialty Focus

Medical Specialties

Oncology

Documentation Requirements

Detailed documentation of the primary cancer diagnosis, staging, and treatment history.

Common Clinical Scenarios

Patients presenting with symptoms of metastatic disease without a known primary site.

Billing Considerations

Ensure all diagnostic tests and imaging results are documented to support the coding of C79.9.

Palliative Care

Documentation Requirements

Comprehensive documentation of symptom management and quality of life assessments.

Common Clinical Scenarios

Patients with advanced cancer requiring symptom relief and supportive care.

Billing Considerations

Document the goals of care discussions and patient preferences.

Coding Guidelines

Inclusion Criteria

Use C79.9 When
  • According to ICD
  • 10 coding guidelines, C79
  • 9 should be used when the metastatic site is not specified
  • Coders must ensure that all efforts to identify the primary site have been documented
  • If the primary site is later identified, the code should be updated accordingly

Exclusion Criteria

Do NOT use C79.9 When
No specific exclusions found.

Related ICD-10 Codes

Related CPT Codes

99214CPT Code

Established patient office visit, level 4

Clinical Scenario

Used for follow-up visits for patients with metastatic disease.

Documentation Requirements

Document the patient's history, examination findings, and treatment plan.

Specialty Considerations

Oncology specialists should ensure comprehensive documentation of cancer history.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of secondary malignancies, improving the granularity of data collected for metastatic disease. C79.9 captures cases where the primary site is unknown, which can impact treatment planning and resource allocation.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of secondary malignancies, improving the granularity of data collected for metastatic disease. C79.9 captures cases where the primary site is unknown, which can impact treatment planning and resource allocation.

Reimbursement & Billing Impact

reimbursement.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

When should I use C79.9?

C79.9 should be used when a patient has a secondary malignant neoplasm, and the specific site of metastasis is not documented or is unknown. Ensure that all efforts to identify the primary site have been documented.